Skip to main content
. 2021 Jul 8;22(14):7367. doi: 10.3390/ijms22147367

Figure 5.

Figure 5

Activation of the Akt/mTOR pathway in human myotubes on day 8 of differentiation and after 48 h of treatment with tideglusib and VP0.7 at three concentrations (1.2, 3.0 and 15.0 µM) in control (n = 1) and patient LGMDR1 (n = 1): (A) western blot of AKT, P-AKT (Ser473), mTOR, P-mTOR (Ser2448 and Ser2481), p70S6K, P-p70S6K (Thr421/Ser424), P-p70S6K (Thr389), P-RPS6 (Ser235/Ser236) and P-AMPK (Thr172). (B) Effect of FRZB silencing on the mTOR pathway in controls’ (n = 2) and LGMDR1 patients’ (n = 3) myotubes. The red squares in the WB show the lowest concentration used in patients (1.2 µM) for densitometry analysis. For the quantification of total AMPKα in LGMDR1 patient’s myotubes, only the lowest dose was analyzed.